HOPO-101

The HOPO Project: Next-Generation Chelation

While Ca-DTPA and Zn-DTPA remain the current standard for gadolinium chelation therapy, a next-generation chelator called HOPO (3,4,3-LI(1,2-HOPO), also known as HOPO-101) is under active development by HOPO Therapeutics. HOPO-101 is designed to be a more effective and better-tolerated chelating agent for toxic heavy metals, including gadolinium. It was originally developed at Lawrence Berkeley National Laboratory and has demonstrated significantly higher binding affinity for gadolinium compared to DTPA in preclinical studies.

One of the key advantages of HOPO-101 is that it is being developed as an oral medication, which would eliminate the need for IV infusions and make chelation therapy far more accessible to patients. Additionally, HOPO-101 appears to cause less mineral depletion than DTPA, which could reduce one of the most significant side effects of current chelation therapy. The drug is currently in clinical trials and is not yet available for general use.

For patients currently undergoing DTPA chelation, HOPO-101 represents a promising future option that may offer improved efficacy, convenience, and tolerability. However, it is important to note that HOPO-101 is still investigational and has not received FDA approval. Patients should continue to work with their providers on currently available treatment options while monitoring the progress of the HOPO clinical development program.